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Abstract
Background:  Malta has one of the lowest incidence rates 
of tuberculosis in Europe and a comprehensive free-of-charge 
health care system.
Objective: To investigate whether Malta satisfies the 
criteria recommended by the International Union Against 
Tuberculosis and Lung Disease (IUATLD) in order to consider 
the discontinuation of the present school BCG vaccination 
programme.
Method: Review of World Health Organization (WHO), 
and IUATLD guidelines for BCG use and discontinuation. 
Examination of surveillance data pertaining to tuberculosis in 
Malta, for the years 1979 to 2008.
Findings:  Malta has a long-standing, well-developed 
surveillance, treatment and follow-up programme for 
tuberculosis. The average annual notification rate of smear 
positive pulmonary tuberculosis was about 2 per 100,000 
person-years since 1990. This is well below rates recommended 
by the IUATLD for the discontinuation of routine BCG 
vaccination programs. 
Conclusion:  Malta satisfies established international 
criteria for discontinuation of the school BCG vaccination 
programme and therefore the programme should be re-
considered. 
Introduction  
Routine mass immunisation with the Bacille Calmette-
Guérin (BCG) vaccine has been a contentious issue since its 
inception. The BCG vaccine was first used in humans in 1921 
but received a setback in 1930 following a disaster in Lübeck. 
Immediately after World War II, mass immunisation in many 
European countries was introduced as an emergency measures. 
However this was based on evidence which was far from clear. 
In addition, many studies on the efficacy of BCG vaccination 
have shown extensive variation compelling WHO to review 
the efficacy of the vaccine in 1959 and again in 1979. The WHO 
subsequently changed its recommendations in 1983.1 
In the early 1950s, major trials were set up by the British 
Medical Research Council (MRC) and by the United States 
Public Health Service, to determine the efficacy of routine 
BCG vaccination. The procedure employed by the British MRC 
showed high efficacy against tuberculosis in early adulthood, 
in contrast to the American experience which did not. BCG 
vaccination was subsequently recommended as a routine 
procedure for tuberculin-negative adolescents in the UK, while 
in the USA, BCG vaccination was limited to certain high-risk 
populations.2-4  The British MRC showed that the vaccine had 
a protective efficacy of 75–80% lasting 10–15 years. At that 
time, in the UK-born population, TB was commonest amongst 
those aged 15 to 29 years.  Hence it was thought reasonable to 
vaccinate all tuberculin negative schoolchildren between the 
ages of 11-13 years to provide subsequent protection. Malta, 
then a British colony, followed suit as regards the adoption 
and timing of BCG immunisation. Even before 2005, the UK 
had satisfied the IAUTLD criteria for discontinuing the school 
BCG vaccination program, and this was subsequently stopped. 
The current UK guidelines recommend that vaccination efforts 
are targeted towards those most at risk, and discontinued in 
low-incidence and low-risk populations.5 In the UK targeted 
use of the BCG vaccine is currently recommended because 
of evidence of its efficacy in infancy by reducing, pulmonary 
disease, disseminated and tuberculous meningitis, and mortality 
from TB.5
The epidemiological pattern of TB in Malta closely resembles 
that found in the UK today: very high rates in persons born 
in high TB-endemic regions, and very low levels in the native 
population. In addition, Malta has a lower national TB incidence 
rate and a lower annual risk of infection rate than in the UK.5,6 
In 2002, the Malta Tuberculosis Working Group called for 
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the reconsideration of the School BCG Programme in Malta 
as the IUATLD criteria had been reached. It was decided at 
the time to continue the vaccination program mainly because 
of uncertainties resulting from the changing epidemiological 
picture in Malta: in that year, an unusual number of irregular 
migrants from high TB and high HIV-incidence regions 
started to arrive in Malta. The UK had earlier on faced similar 
concerns.4 To date, Malta has a routine school BCG vaccination 
program, for children between 11 and 12 years of age, who are 
Mantoux negative (0-4mm). This non-mandatory but highly 
recommended program is offered free-of-charge to all children, 
and has a coverage of more than 78 % (Table 1).
The incidence of TB in native-born populations of most 
western European countries, including Malta has been falling 
again since the early 1990`s.6 In view of this favourable situation, 
school and neonatal BCG vaccination programmes in many of 
these countries have been reviewed, modified or discontinued.7 
The decision to discontinue mass vaccination in a given 
population and change to selective or targeted vaccination is 
based on criteria produced by the IUATLD as recommended by 
WHO. The criteria were produced to help national immunisation 
advisory bodies to examine local epidemiological data and 
reach a decision on the future of their routine immunisation 
programmes.8
The BCG vaccine is one of the most widely used vaccines, 
with a coverage of more than 80% in neonates and infants 
in developing countries where it forms part of the national 
childhood immunisation programs, in accordance with WHO 
position documents.9 This vaccine has a documented protective 
effect against tuberculous meningitis and disseminated disease 
in children, especially neonates. However, it neither prevents 
primary infection nor reactivation of latent pulmonary infection. 
It does not appreciably reduce the number of infectious persons, 
the principal source of airborne bacillary spread, and so the 
vaccine has a minimal role in lessening the incidence of TB at 
a community level.9 BCG immunisation is thought to reduce 
post-primary mycobacterial haematogenous spread in young 
children and therefore reduces miliary or disseminated TB and 
TB meningitis. BCG immunisation can be life-saving in younger 
children since they have an increased risk of progression to 
active disease.10 It has been shown that once infected, children 
under 12 months have a 43% increased risk of progression to 
acute disease, 1 to 5 year-olds have a 24% increased risk, while 
adolescents have a 15% increased risk of progression.11
     The protection offered against adult forms of the disease 
is uncertain. Studies on BCG vaccination, from different areas 
of the world have shown variable efficacy rates ranging from 
0 to 80%.10 Exposure to and infection with environmental 
mycobacteria, more frequently found in hot climates, induces 
some immunity in the body.2 The resulting increased immunity 
towards mycobacteria in general probably masks any protection 
BCG vaccination may provide.10 Differences of human exposure 
to environmental mycobacteria is the most likely explanation 
for the wide range in efficacy of the various immunisation 
programmes. These inconsistent results have led to the 
adoption of diverse BCG vaccination programmes by different 
countries.2  
The World Health Organization, through the Expanded 
Immunization Programme (EPI), recommends BCG vaccination 
for infants at birth (or as soon as possible thereafter) in high-
risk and high-incidence populations.11 High-risk regions 
include Eastern Europe, sub-Saharan Africa, South East 
Asia and the Middle East. Booster doses of BCG are not 
recommended by WHO, as there is no documented value in 
this policy.12 BCG vaccination is contraindicated in persons with 
impaired immunity including known or suspected congenital 
immunodeficiency, leukaemia, lymphoma, generalised 
     
  Mantoux  Mantoux Prevalence  
 Total tested Mantoux tested = positive  
Scholastic population negative tested positive (≥10mm) Annual risk
Year	 tested	 0-4mm	 5-9mm	 ≥	10mm	 tested	%	 of	infection	(R)
2001-2 4792 4641 107 44 0.918 0.188
2002-3 5135 4992 111 32 0.507 0.057
2003-4 4948 4819 100 29 0.586 0.071
2004-5 4609 4398 184 27 0.586 0.071
2005-6 2792 2672 102 18 0.645 0.083
2006-7 6428 6113 251 64 0.996 0.369
2007-8 4561 4446 90 25 0.548 0.064
Table 2: Annual risk of infection (R) in children by scholastic year
 Total  
 11-12 year old  
 population   
	 considered	for	 Population	 %
Year vaccination vaccinated vaccinated
2001-2 5517 4637 84
2002-3 5887 4810 82
2003-4 5716 4819 84
2004-5 5321 4392 83
2005-6 3403 2651 78
2006-7 7240 6076 84
2007-8 5287 4438 84
Table 1: Number and percentage vaccinated 
by scholastic year
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malignant disease, immunosuppressive therapy, pregnancy 
and in asymptomatic HIV-positive persons.13,14 Countries with 
a low burden of TB may choose to limit BCG vaccination to 
neonates and infants of recognised high-risk groups for the 
disease. The routine use BCG vaccination for tuberculin-negative 
older children depends on the epidemiological situation found 
in specific communities. In some low-burden populations, 
BCG vaccination has been largely replaced by intensified case 
detection and supervised early treatment.9
In 1994, the IUATLD had suggested criteria under which it 
was reasonable for a country with low TB prevalence, to consider 
a shift from routine mass BCG vaccination programmes towards 
targeted vaccination of high-risk groups. A well-functioning 
National TB control programme with an efficient notification 
system had to be in place including one of the following 
conditions:
a.  The average annual notification rate of smear positive 
pulmonary tuberculosis is 5 per 100,000/year or less 
during the previous three years.
b.  The average annual notification rate of tuberculous 
meningitis in children under five years of age is less than 
1 per 10 million population over the previous five years,   
c.  The average annual risk of tuberculous infection is below 
0.1%.8 
Methods
     The IUATLD criteria for evaluation of National TB Control 
Programmes were considered as no other similar guidelines 
could be found. 
     All TB-related data were obtained from the Chest Clinic/
Unit which also functions as a TB surveillance unit for Malta. 
The number of smear (Ziehl–Neelsen stain) positive cases of 
pulmonary tuberculosis and the number of children less than 
five years of age notified with tuberculous meningitis were 
collected. Comprehensive TB-related medical care at this Clinic 
is free-of-charge; contact tracing is also performed and persons 
with latent TB infections are treated or advised accordingly. 
Diagnosing physicians are required by law to notify all forms 
of tuberculosis. The few patients who were treated privately 
were identified, as anti-TB medications cannot be obtained 
commercially, and their prescription is restricted to specified 
physicians. Free-of-charge anti-TB medication is only dispensed 
by two state pharmacies and the Chest Clinic is notified regularly 
of all such medication dispensed in Malta. Almost all patients 
suffering from TB, including those diagnosed privately, were 
referred to the Chest Clinic, and those who were not, were still 
followed up by the Clinic. This Clinic also receives laboratory 
notification of all smear and culture positive results for TB, 
including those for environmental mycobacteria.     
Information about the denominator populations for 
each specific age-group and for each year (end of year) 
investigated was derived from data provided in the National 
Statistics Office yearly demographic reviews.15 These were 
used to calculate the incidence rates. TB cases included those 
with a definite (bacteriologically confirmed) and other than 
definite (histological, radiological and/or clinically confirmed) 
diagnosis, and who were treated with standard short-course 
chemotherapy. 
It is a long-standing laboratory policy to screen all samples 
obtained from patients suspected of having TB with the Ziehl–
Neelsen stain and to culture on Lowenstein-Jensen medium 
for acid-fast bacilli (AFB). All cultures positive for AFB were 
referred for species identification and drug sensitivity testing 
to a national reference laboratory in the UK. TB cases used for 
estimation of incidence included all cases diagnosed in Malta de 
novo and relapses. New TB cases were included for estimation 
of national incidence and were separated into Malta-born and 
foreign-born. For estimation of sputum positive cases, native, 
foreign-born and relapse cases were combined as all these 
categories are deemed infectious.
The average annual risk of tuberculous infection is estimated 
by using tuberculin based population surveys. The results of 
Mantoux testing prior to school BCG vaccination, over seven 
consecutive scholastic years (2002-2008), in Malta were used 
(Table 2): transverse diameters of 0 to 4mm induration were 
considered as a negative result and eligible for vaccination, 
Figure 1: Incidence of tuberculosis: total 
and among the Malta-born population
Figure 2: Incidence of TB in the pre-vaccination 
Malta-born 0-10 year age group
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diameters of 5 to 9mm were considered as intermediate and 
not requiring vaccination, while diameters of 10mm and over 
were considered as positive and warranted further contact 
investigation. Children with the latter result were referred to 
exclude TB in both self and all other household members. The 
average annual risk of tuberculous infection was calculated by 
using the results of Mantoux testing (Table 2) and the equation 
R=1-(1-P)1/a, where R stands for annual risk of infection, a 
is the average age at which prevalence is calculated and P 
the prevalence. This method to calculate the average annual 
risk of infection is derived from a formula by Nyboe,16 and 
although it suffers from a number of shortcomings as shown 
by Rieder,17 may be useful as a method of measurement. The 
prevalence P of TB infection was calculated by using the pre-
vaccination numbers of positive Mantoux results. The value of 
a represents the average age of Mantoux screening: from their 
11th to 13th birthday. High-risk indicates an incidence of at least 
40/100,000 person-years and low-risk incidence is considered 
as 20/100,000 person-years or less.5
Results  
With a long-standing, well-developed surveillance, 
treatment and follow-up National TB programme, Malta has one 
of the lowest TB incidences in Western Europe. The downward 
trend in TB incidence in the Malta-born population has been 
maintained (Figure 1). Directly Observed Treatment, short-
course chemotherapy, treatment outcome monitoring, good 
pharmaceutical services and consistent political support have 
helped to achieve WHO recommended targets. The absence of 
local drug-resistant TB is a good indicator of adequate local 
treatment.17 The highest incidence of TB occurs amongst the 
elderly population and continues to fall.18 There have been no 
notifications of TB in Malta-born children for at least 8 years 
(Figures 2 and 3). 
The yearly average incidence of smear-positive pulmonary 
TB since 1990 was 2/100,000 person-years: this even includes 
cases of smear positive samples from which no organisms were 
cultured and could probably have included atypical mycobacteria 
(Figure 4). This satisfies IUATLD criterion a.
As regards meningeal tuberculosis, there was only one case 
since 1979: a 5 year-old child notified in 1991. This rate, given 
the small size of the population, at around 410,000, is negligible: 
the latter and the time span satisfy criterion b. 
The calculated average annual risk of tuberculous infection 
in 11 to 12 year old children over a seven-year period is 0.13%, 
or 0.089% if an anomalous scholastic year (2006/2007) is 
excluded (Table 1). Mantoux testing in the current circumstances 
of very low TB incidence is also expected to produce a high 
rate of false-positive results. In fact children who were pre-
vaccination Mantoux-positive, were examined further and 
tested with the interferon gamma release assay (IGRA) 
available (QuantiFERON®TB Gold Test) with the result that 
approximately one third were subsequently found to be 
positive.19 At such low prevalence rates even the IGRA itself 
could still be expected to produce a number of false positive 
results. The scholastic year 2005/2006 featured a lower than 
usual number of children considered for Mantoux screening 
due to an influenza epidemic which disrupted the service. 
The following scholastic year 2006/2007 showed a number 
of children carried over from the previous year and resulted 
in a higher number screened. The resultant higher annual risk 
of infection could represent an anomalous and biased result. 
The annual risk of infection R fell again to the usual range the 
following scholastic year (2007/2008).
Discussion  
The incidence of tuberculosis in Malta remains very low at 
less than 15 per 100,000 person years, in spite of the large influx 
of irregular immigrants and other foreign-born persons coming 
from high incidence countries, especially since 2002. 
The incidence of smear positive pulmonary TB has been 
below 5 per 100,000/person - years since at least 1987. This 
finding provides evidence and is a good indicator of the small 
number of individuals in the community with the ability to infect 
other persons and maintain ongoing TB prevalence.
Children are more easily infected by the mycobacterium 
and more frequently go on to develop, often fatal, acute disease. 
The incidence of TB meningitis, in highly susceptible children 
under the age of five, gives a good indication of on-going TB 
infectious disease in the community and is approximately 1% 
of the annual risk of TB infection.10 Children usually develop 
much less infectious forms of the disease because they rarely 
Figure 3: Incidence of TB in the 
Malta-born 13-23 year age group
Figure 4: Total incidence, including relapses, 
of smear positive pulmonary TB in Malta
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produce sputum, and if samples are obtained, they are seldom 
smear-positive.20 The likelihood of native children coming into 
contact with infectious TB in irregular migrants, a high-risk 
population, and becoming infected is unlikely. Children could be 
targeted for BCG vaccination at birth, if coming from high-risk 
groups. These would include children born in high TB-incidence 
countries or born in Malta where the provenance of at least one 
parent (or grand-parent) is from a region with a high incidence 
of tuberculosis.
The age (11-12 years) at which the vaccine is routinely offered 
in Malta, can certainly not provide any direct protection from 
TB in the most susceptible group: those less than 11 years of 
age. Despite the increased susceptibility, this age group had 
not shown any increase in miliary, meningeal, or pulmonary 
TB, moreover this grou’s estimated annual risk of infection was 
very low. Incidence of TB in this pre-vaccinated group showed 
a decline of approximately 4.3% per year from 1979 to 2000 
and after this year there were no cases reported (Figure 2). 
These favourable findings indicate very low levels of ongoing TB 
infection in the community. Mantoux testing prior to school BCG 
vaccination (Table 2) did not show any marked or consistent 
increase in Mantoux positivity over the years 2002-2008, 
coincident with increased immigrant arrivals.  
Consideration must also be given to the adverse effects of the 
vaccine; if the risk of disease is estimated to be much lower than 
the risk of serious vaccine adverse reactions, then a mass vaccine 
program should be reconsidered. Although the vaccine is known 
to be extremely safe, significant local reactions, such as extensive 
local ulceration and regional lymphadenitis occur in less than 1 
per 1000 vaccinations. Other estimates per million vaccinations 
include a range of 1.7-72.9 cases of osteitis, and a range of 0.19-
1.56 cases of disseminated BCG disease.10,21 Considering these 
complication rates, Malta can expect at least one to two children 
developing a serious local adverse reaction each year. The risk 
of developing adverse events also varies by population, age, 
vaccine strain, dose, immune status, HIV status, site and depth 
of injection and technique of administration.2 It would seem that 
the incidence of tuberculosis (figure 3) is now much less than 
the adverse reactions expected from the vaccine. 
In conclusion, Malta satisfies the criteria proposed by 
the IUATLD to consider discontinuation of the routine mass 
BCG vaccination programme, and in turn it may no longer 
be reasonable, or even safe, to encourage routine school BCG 
vaccinations for the Malta-born, 11 to 12 year-old population. 
It may be recommended that a new policy document regarding 
targeted BCG immunization be drawn up and that surveillance 
should be continued to specifically monitor the effect of 
stopping the programme. Cost savings should be estimated and 
possibly diverted to strengthen other more pressing activities 
of the National TB Programme. One of the greatest threats 
to public health security is the very high incidence of TB in 
irregular immigrants coming to Malta from high-TB and high-
HIV prevalence areas of the world. Any re-organisation of the 
National TB programme should take into account this changing 
demographic pattern in Malta.
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